JSH-23: A Precise Small Molecule NF-κB Inhibitor for Inflammation Research

Executive Summary: JSH-23 (CAS 749886-87-1) is a small-molecule inhibitor that targets NF-κB p65 nuclear translocation and transcriptional activity, with an IC50 of ~7.1 μM in cellular assays (APExBIO, product page). The compound does not impede IκB degradation but effectively inhibits the expression of pro-inflammatory mediators (e.g., IL-6, TNF-α, COX-2, IL-1β) in LPS-stimulated RAW 264.7 macrophages. In vivo, JSH-23 reduces biomarkers of inflammation and tissue injury in models such as cisplatin-induced acute kidney injury in C57BL/6 mice (Li et al., 2025). Its solubility, stability, and selectivity make it a robust research tool for mechanistic studies of NF-κB signaling.

Biological Rationale

NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) is a central transcription factor complex regulating immune and inflammatory responses. Aberrant activation of NF-κB is implicated in the pathogenesis of chronic inflammatory diseases, including inflammatory bowel disease and acute kidney injury (Li et al., 2025). The canonical NF-κB pathway involves cytoplasmic retention of NF-κB dimers by IκB proteins; upon stimulation (e.g., LPS, cytokines), IκB is phosphorylated and degraded, allowing NF-κB (notably the p65 subunit) to translocate into the nucleus and drive transcription of target genes. Targeted inhibition of NF-κB p65 nuclear translocation and DNA binding—without globally suppressing upstream signaling—enables fine-tuned interrogation of inflammatory gene expression programs. JSH-23, developed and distributed by APExBIO, was designed to fulfill this need for selective, reversible NF-κB inhibition in both cellular and animal models (APExBIO).

Mechanism of Action of JSH-23

JSH-23 is chemically designated as 4-methyl-1-N-(3-phenylpropyl)benzene-1,2-diamine (C16H20N2, MW 240.34). It inhibits NF-κB-mediated gene transcription by preventing the nuclear localization and DNA binding activity of the NF-κB p65 (RelA) subunit. Notably, JSH-23 does not affect IκB degradation, distinguishing it from upstream inhibitors such as IKK inhibitors. In LPS-stimulated RAW 264.7 macrophages, JSH-23 at micromolar concentrations blocks p65 nuclear translocation within 1–3 hours of exposure, leading to rapid downregulation of pro-inflammatory cytokines (IL-6, IL-1β, TNF-α) and enzymes (COX-2) (Li et al., 2025). This selective mechanism permits temporal and mechanistic dissection of NF-κB-dependent transcriptional events (Article: Precision NF-κB Inhibition).

Evidence & Benchmarks

• JSH-23 exhibits an IC50 of 7.1 μM for inhibition of NF-κB transcriptional activity in cell-based assays (APExBIO).
• Selective inhibition of p65 nuclear translocation and DNA binding is achieved without blocking IκB degradation (APExBIO).
• In LPS-stimulated RAW 264.7 macrophages, JSH-23 reduces mRNA and protein levels of IL-6, IL-1β, TNF-α, and COX-2 within 4 hours (Li et al., 2025).
• In cisplatin-induced acute kidney injury (male C57BL/6 mice, i.p. JSH-23), significant reduction is observed in BUN, serum creatinine, NGAL, IL-1, IL-6, CXCL1, and TNF-α levels, as well as acute tubular necrosis scores and MPO activity (Li et al., 2025).
• JSH-23 is soluble at ≥24 mg/mL in DMSO and ≥17.1 mg/mL (with sonication) in ethanol, but insoluble in water; optimal storage is at -20°C (APExBIO).

This article extends the analysis found in Harnessing Precision NF-κB Inhibition: JSH-23 as a Strategy by presenting new quantitative in vivo evidence and specifying solubility/storage parameters for reproducible workflows.

Applications, Limits & Misconceptions

JSH-23 is used to:

• Dissect NF-κB signaling in inflammation research.
• Model the impact of selective NF-κB p65 inhibition in animal and cell-based disease models.
• Validate NF-κB-dependent gene targets and regulatory elements.
• Serve as a benchmark compound in the development or comparison of novel anti-inflammatory agents.

For comparison, JSH-23: Next-Gen NF-κB Inhibitor for Precision Inflammation emphasizes its selectivity and translational value, whereas this dossier provides explicit chemical, storage, and application benchmarks.

Common Pitfalls or Misconceptions

• JSH-23 is not an IKK or upstream NF-κB pathway inhibitor and does not prevent IκB degradation.
• Ineffective in models where inflammation is not mediated by the canonical NF-κB p65 pathway.
• Not suitable for aqueous-only systems due to insolubility in water; use DMSO or ethanol (with sonication) for stock solutions.
• Long-term solution storage is not recommended; prepare fresh aliquots for each experiment.
• Does not inhibit inflammasome activation independently of NF-κB priming steps (Li et al., 2025).

Workflow Integration & Parameters

JSH-23 is supplied as a solid by APExBIO (SKU: B1645). For in vitro use, dissolve in DMSO to ≥24 mg/mL; for ethanol, use sonication to achieve ≥17.1 mg/mL. Solutions should be freshly prepared and stored at -20°C. For cell-based assays, working concentrations typically range from 5–20 μM, applied for 1–6 hours depending on cell type and endpoint. In animal studies (e.g., mice), intraperitoneal injection is the common route, with dosing and frequency tailored to the experimental model (e.g., single or repeated doses in acute kidney injury paradigms). For detailed experimental design guidance, see JSH-23: Advanced Insights into NF-κB Inhibition for Translational Studies, which this article updates by including new in vivo efficacy and solubility data.

Conclusion & Outlook

JSH-23 stands as a validated, selective inhibitor of NF-κB p65 nuclear translocation, enabling high-precision studies of inflammatory signaling. Its robust performance in both cellular and animal models supports its ongoing adoption in inflammation research, particularly where dissecting NF-κB-dependent transcription is essential. As further data emerges, especially in translational disease models, JSH-23 will remain a key tool for mechanistic and preclinical studies. For comprehensive specifications and procurement, refer to the APExBIO JSH-23 product page.